La cadena de opciones muestra datos clave de las opciones de acciones de Pyxis Oncology a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Pyxis Oncology..

Pyxis Oncology (NASDAQ:PYXS) Bolsa, Cadena de Opciones

PYXIS ONCOLOGY INC

Pyxis Oncology

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

<p>American Express Global Business Travel which is operated by Global Business Travel Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTG#NYSE">GBTG</a>) ("Amex GBT" or the "Company"), a leading software and services company for travel, expense and meetings &amp; events, today announced that the United States Department of Justice ("DOJ") has dismissed its complaint challenging Amex GBT's acquisition of CWT, aglobal business travel and meetings solutions provider.</p>
<p>"We recognize the regulatory approval process has created uncertainty for CWT customers and employees. We're excited to close the transaction and welcome them to Amex GBT. Together, we will offer customers unrivalled choice, value, and experience," said Amex GBT CEO Paul Abbott.</p>
<p>"We are pleased that the DOJ has come to this conclusion," said CWT CEO, Patrick Andersen. "Our customers and people have an exciting future ahead of them as we turn our focus to completing the transaction and integrating with Amex GBT. Together we can provide a tech-enabled future for business travel, where people and technology combine to deliver an exceptional customer experience."</p>
<p>We expect the transaction to be highly accretive with approximately $155 million of identified net synergies. The transaction is valued at $540 million, made up of approximately 50 million shares to be issued at a fixed price of $7.50 per share, with the remaining consideration funded with cash on hand. The result will be a more diverse shareholder base, with CWT shareholders owning approximately 10% of the combined company. The transaction is now expected to close in the third quarter, subject to the satisfaction of the remaining closing conditions.</p>


News

GBTG

American Express Global Business Travel Says US DOJ Dismisses Its Complaint Challenging Amex GBT's Acquisition Of CWT; Transaction Now Expected To Close In Q3

<p>Cryptocurrency markets are trading sideways one day ahead of the Federal Reserve&#8217;s decision on interest rates.</p>
<p><figure class="wp-block-table"><br />
<table class="has-fixed-layout">
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Ticker</strong></td>
<td><strong>Price</strong></td>
</tr>
<tr>
<td><strong>Bitcoin</strong></td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$117,766.69</td>
</tr>
<tr>
<td><strong>Ethereum</strong></td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$3,772.28</td>
</tr>
<tr>
<td><strong>Solana</strong></td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$181.58</td>
</tr>
<tr>
<td><strong>XRP</strong></td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$3.14</td>
</tr>
<tr>
<td><strong>Dogecoin</strong></td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$181.58</td>
</tr>
<tr>
<td><strong>Shiba Inu</strong></td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001313</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Notable Statistics:</strong></p>
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin's large transaction and daily active addresses increased by 39.4% and 62.7%, respectively. Exchanges netflows narrowed by 362.8%.</li>
<li>Coinglass data shows 165,599 traders were liquidated in the past 24 hours for $448.33 million.&nbsp;</li>
</ul>
<p><strong>Notable Developments:</strong></p>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46696965/another-ethereum-treasury-play-180-life-sciences-raises-425-million-to-buy-eth">Another Ethereum Treasury Play: 180 Life Sciences Raises $425 Million To Buy ETH</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46699147/kuvi-ai-raises-700000-seed-round-to-launch-private-beta-of-agentic-finance-operating-system">Kuvi.ai Raises $700,000 Seed Round To Launch Private Beta Of Agentic Finance Operating System</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46699508/ethereum-treasuries-could-soon-own-10-of-all-eth-standard-chartered">Ethereum Treasuries Could Soon Own 10% Of All ETH: Standard Chartered</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46683578/chinese-bitcoin-mining-tech-producer-bitmain-is-betting-big-on-america-but-why">Chinese Bitcoin Mining Tech Producer Bitmain Is Betting Big On America—But Why?</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46685885/take-note-xrp-traders-this-leveraged-etf-is-designed-to-be-traded-each-day">Take Note XRP Traders: This Leveraged ETF Is &#8216;Designed To Be Traded Each Day&#8217;</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46681312/trumps-bitcoin-reserve-just-legitimized-it-coinbase-ceo-brian-armstrong-says-g20-nations-now-rushing-to-build-their-own-btc-stockpiles">Trump&#8217;s Bitcoin Reserve Just &#8216;Legitimized It&#8217;—Coinbase CEO Brian Armstrong Says G20 Nations Now Rushing To Build Their Own BTC Stockpiles</a></li>
</ul>
<p><strong>Trader Notes: </strong>Bitcoin Therapist <a href="https://x.com/TheBTCTherapist/status/1950252467196768496">outlined</a> two key scenarios for Bitcoin:</p>
<ul class="wp-block-list">
<li><strong>Gradual Climb:</strong> Bitcoin slowly trends higher with small pullbacks, ultimately reaching $180,000–$200,000.</li>
<li><strong>Violent Repricing:</strong> A sudden breakout as 18 months of paper BTC accumulation resolves, sending prices soaring to $350,000–$400,000.</li>
</ul>
<p>Roman, however, <a href="https://x.com/Roman_Trading/status/1950200069774246116">urged</a> caution.</p>
<p>He noted that while Bitcoin often consolidates before continuing upward, current weekly timeframe signals tell a different story. A pullback as the more likely near-term outcome, bearish divergences and overly bullish sentiment</p>
<p>Kevin echoed that caution, emphasizing this is a pivotal macro week with the FOMC and key economic data on deck. </p>
<p>He warned that Total2, the altcoin market cap, is at significant resistance and Bitcoin is pressing against the $120,000–$123,000 resistance while remaining below the weekly RSI downtrend.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">Big week this week as we already know with all the macro data and FOMC happening. Holding my opinion that no one should be a hero up at these levels on Total 2 (<a href="https://twitter.com/hashtag/Altcoins?src=hash&amp;ref_src=twsrc%5Etfw">#Altcoins</a> Market Cap). Same goes for <a href="https://twitter.com/hashtag/BTC?src=hash&amp;ref_src=twsrc%5Etfw">#BTC</a> being under the weekly RSI downtrending line of resistance and the 120K-123K… <a href="https://t.co/kJHTZDZvT2">pic.twitter.com/kJHTZDZvT2</a></p>
<p>&mdash; Kevin (@Kev_Capital_TA) <a href="https://twitter.com/Kev_Capital_TA/status/1950156273325875216?ref_src=twsrc%5Etfw">July 29, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Crypto Lord added that Bitcoin's tight consolidation just beneath all-time high after a powerful impulse suggests the top may be close. He advises traders to stay sharp, as upside could be limited before a possible reversal or major correction.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">Bitcoin is trading in a tight consolidation just below its all-time high after its strong impulsive rally.<br /><br />Patience and precision is required, the <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> top is not far away. <a href="https://t.co/ExoecQqr3A">pic.twitter.com/ExoecQqr3A</a></p>
<p>&mdash; Crypto Lord (@Thecryptolord_) <a href="https://twitter.com/Thecryptolord_/status/1950246226881835346?ref_src=twsrc%5Etfw">July 29, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46699964/fomc-meeting-preview-will-jerome-powell-accelerate-the-bitcoin-ethereum-xrp-bull-run">FOMC Meeting Preview: Will Jerome Powell Accelerate The Bitcoin, Ethereum, XRP Bull Run?</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP Remain Muted As Dogecoin Drops Ahead Of FOMC Meeting

<p>Shares of <strong>ScanTech AI Systems Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAI#NASDAQ">STAI</a>) are trading higher Tuesday after the company entered into a procurement contract with Creeksource Consulting LLC, enabling ScanTech AI to offer its advanced screening technologies through The Interlocal Purchasing System (TIPS).</p>
<p>This contract allows government agencies, municipalities, schools and nonprofit organizations to purchase ScanTech's products via a nationally recognized cooperative purchasing platform. The partnership is expected to streamline procurement processes for public entities while opening up what the company estimates to be a $100 million addressable market.</p>
<p>According to the announcement, there are more than 3,000 county courthouses and approximately 13,000 municipal courthouses across the United States, many of which are considered critical infrastructure. </p>
<p><strong>STAI Price Action</strong>: ScanTech shares were up 87.6% at $1.25 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a></p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/news/earnings/25/05/45376829/cyberark-stock-slips-despite-strong-q1-growth-in-subscriptions-and-raised-2025-outlook">CyberArk Stock Slips Despite Strong Q1 Growth In Subscriptions And Raised 2025 Outlook</a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>


Movers

STAI

What's Going On With ScanTech Ai Shares Today?

<p>Newmark Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRK#NASDAQ">NMRK</a>) is preparing to release its quarterly earnings on Wednesday, 2025-07-30. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Newmark Group to report an <strong>earnings per share</strong> (EPS) of $0.26.</p>
<p>Newmark Group bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings Track Record</h3>
<p>In the previous earnings release, the company beat EPS by $0.02, leading to a 1.82% drop in the share price the following trading session.</p>
<p>Here's a look at Newmark Group's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.19</td>
<td>0.48</td>
<td>0.30</td>
<td>0.20</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.21</td>
<td>0.55</td>
<td>0.33</td>
<td>0.22</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>6.0%</td>
<td>-1.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753815807_0.png" alt="eps graph" /></p>
<h3>Newmark Group Share Price Analysis</h3>
<p>Shares of Newmark Group were trading at $13.55 as of July 28. Over the last 52-week period, shares are up 10.86%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/NMRK/earnings"><strong>To track all earnings releases for Newmark Group visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

NMRK

What's Next: Newmark Group's Earnings Preview

<p>Littelfuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFUS#NASDAQ">LFUS</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-07-30. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Littelfuse will report an <strong>earnings per share</strong> (EPS) of $2.34.</p>
<p>The announcement from Littelfuse is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.38, leading to a 1.75% increase in the share price on the subsequent day.</p>
<p>Here's a look at Littelfuse's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.81</td>
<td>2.06</td>
<td>2.09</td>
<td>1.75</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.19</td>
<td>2.04</td>
<td>2.71</td>
<td>1.97</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>5.0%</td>
<td>-3.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753815798_0.png" alt="eps graph" /></p>
<h3>Market Performance of Littelfuse's Stock</h3>
<p>Shares of Littelfuse were trading at $237.17 as of July 28. Over the last 52-week period, shares are down 11.88%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Analyst Observations about Littelfuse</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Littelfuse.</p>
<p>The consensus rating for Littelfuse is Neutral, based on 2 analyst ratings. With an average one-year price target of $234.5, there's a potential 1.13% downside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Belden, Knowles and Bel Fuse, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Belden, with an average 1-year price target of $125.0, suggesting a potential 47.3% downside.</li>
<li>Analysts currently favor an Buy trajectory for Knowles, with an average 1-year price target of $22.0, suggesting a potential 90.72% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Bel Fuse, with an average 1-year price target of $113.25, suggesting a potential 52.25% downside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>In the peer analysis summary, key metrics for Belden, Knowles and Bel Fuse are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Littelfuse</td>
<td>Neutral</td>
<td>3.53%</td>
<td>$207.26M</td>
<td>1.79%</td>
</tr>
<tr>
<td>Belden</td>
<td>Buy</td>
<td>16.65%</td>
<td>$245.84M</td>
<td>4.13%</td>
</tr>
<tr>
<td>Knowles</td>
<td>Buy</td>
<td>10.36%</td>
<td>$53.30M</td>
<td>1.04%</td>
</tr>
<tr>
<td>Bel Fuse</td>
<td>Outperform</td>
<td>10.55%</td>
<td>$58.82M</td>
<td>7.66%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Littelfuse ranks in the middle for Consensus rating. It is at the bottom for Revenue Growth and Gross Profit, but at the top for Return on Equity among its peers.</p>
<h3>Get to Know Littelfuse Better</h3>
<p>Littelfuse is a primary provider of circuit protection products (such as fuses and relays) into the transportation, industrial, telecommunications, and consumer electronics end markets. The firm is also increasing its power semiconductor business, where it predominantly serves industrial end markets and is breaking into electric vehicle charging infrastructure. Littelfuse has 17,000 global employees.</p>
<h3>Littelfuse's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Littelfuse displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>3.53%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>7.86%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>1.79%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Littelfuse's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.12%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Littelfuse's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.36</strong>.</p>
<p><a href="https://www.benzinga.com/quote/LFUS/earnings"><strong>To track all earnings releases for Littelfuse visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


LFUS

Exploring Littelfuse's Earnings Expectations

<p><strong>Hawkins</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWKN#NASDAQ">HWKN</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-07-30. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Hawkins will report an <strong>earnings per share</strong> (EPS) of $1.34. </p>
<p>Hawkins bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.03, which was followed by a 0.71% drop in the share price the next day.</p>
<p>Here's a look at Hawkins's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2025</strong></th>
<th><strong>Q3 2025</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.75</td>
<td>0.92</td>
<td>1.18</td>
<td>1.01</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.78</td>
<td>0.72</td>
<td>1.16</td>
<td>1.38</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-8.0%</td>
<td>-9.0%</td>
<td>17.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753815788_0_0.png" alt="eps graph" /></p>
<h3>Market Performance of Hawkins's Stock</h3>
<p>Shares of Hawkins were trading at $160.85 as of July 28. Over the last 52-week period, shares are up 53.63%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Insights on Hawkins</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Hawkins.</p>
<p>The consensus rating for Hawkins is Buy, derived from 1 analyst ratings. An average one-year price target of $160.0 implies a potential 0.53% downside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Olin, Tronox Holdings and Kronos Worldwide, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Olin, with an average 1-year price target of $23.6, suggesting a potential 85.33% downside.</li>
<li>Analysts currently favor an Buy trajectory for Tronox Holdings, with an average 1-year price target of $7.2, suggesting a potential 95.52% downside.</li>
<li>Analysts currently favor an Sell trajectory for Kronos Worldwide, with an average 1-year price target of $7.75, suggesting a potential 95.18% downside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>Within the peer analysis summary, vital metrics for Olin, Tronox Holdings and Kronos Worldwide are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hawkins</td>
<td>Buy</td>
<td>10.00%</td>
<td>$52.24M</td>
<td>3.56%</td>
</tr>
<tr>
<td>Olin</td>
<td>Neutral</td>
<td>0.54%</td>
<td>$148.70M</td>
<td>0.06%</td>
</tr>
<tr>
<td>Tronox Holdings</td>
<td>Buy</td>
<td>-4.65%</td>
<td>$99M</td>
<td>-6.46%</td>
</tr>
<tr>
<td>Kronos Worldwide</td>
<td>Sell</td>
<td>2.30%</td>
<td>$106.80M</td>
<td>2.18%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Hawkins ranks highest in Revenue Growth among its peers. It also leads in Gross Profit. However, it has the lowest Return on Equity.</p>
<h3>Delving into Hawkins's Background</h3>
<p>Hawkins Inc manufactures and sells a variety of chemicals and ingredients. The firm organizes itself into three segments based on the product type. The industrial segment, which generates the majority of revenue, sells private label bleach, caustic soda, sulfuric acid, hydrochloric acid, phosphoric acid, potassium hydroxide, and aqua ammonia. The water treatment segment sells chemicals and equipment used to treat potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool water. The health and nutrition segment sells ingredients to food, beverage, personal care, and dietary supplement producers. The majority of revenue is gained from Water Treatment.</p>
<h3>Key Indicators: Hawkins's Financial Health</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Hawkins's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>10.0%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Hawkins's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>6.66%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>3.56%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Hawkins's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.21%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.35</strong>.</p>
<p><a href="https://www.benzinga.com/quote/HWKN/earnings"><strong>To track all earnings releases for Hawkins visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


HWKN

Earnings Outlook For Hawkins

<p>Financial giants have made a conspicuous bullish move on Exxon Mobil. Our analysis of options history for Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) revealed 16 unusual trades.</p>
<p>Delving into the details, we found 56% of traders were bullish, while 37% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $123,060, and 13 were calls, valued at $2,192,597.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $100.0 to $135.0 for Exxon Mobil over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Exxon Mobil stands at 3251.42, with a total volume reaching 9,136.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Exxon Mobil, situated within the strike price corridor from $100.0 to $135.0, throughout the last 30 days.</p>
<h3>Exxon Mobil Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753815788_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$3.55</td>
<td>$3.4</td>
<td>$3.45</td>
<td>$115.00</td>
<td>$1.3M</td>
<td>5.9K</td>
<td>4.1K</td>
</tr>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$1.49</td>
<td>$1.43</td>
<td>$1.45</td>
<td>$125.00</td>
<td>$253.7K</td>
<td>6.5K</td>
<td>1.7K</td>
</tr>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/01/25</td>
<td>$1.72</td>
<td>$1.7</td>
<td>$1.72</td>
<td>$112.00</td>
<td>$91.1K</td>
<td>4.9K</td>
<td>962</td>
</tr>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/15/26</td>
<td>$4.1</td>
<td>$3.85</td>
<td>$4.09</td>
<td>$125.00</td>
<td>$86.0K</td>
<td>0</td>
<td>422</td>
</tr>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.8</td>
<td>$5.7</td>
<td>$5.8</td>
<td>$115.00</td>
<td>$58.0K</td>
<td>7.3K</td>
<td>150</td>
</tr>
</tbody>
</table>
</p>
<h3>About Exxon Mobil</h3>
<p>ExxonMobil is an integrated oil and gas company that explores for, produces, and refines oil worldwide. In 2023, it produced 2.4 million barrels of liquids and 7.7 billion cubic feet of natural gas per day. At the end of 2023, reserves were 16.9 billion barrels of oil equivalent, 66% of which were liquids. The company is one of the world's largest refiners, with a total global refining capacity of 4.5 million barrels of oil per day, and is one of the world's largest manufacturers of commodity and specialty chemicals.</p>
<p>Following our analysis of the options activities associated with Exxon Mobil, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Exxon Mobil</h3>
<ul>
<li>Trading volume stands at 9,407,775, with XOM's price up by 1.05%, positioned at $112.61.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 3 days.</li>
</ul>
<h3>What Analysts Are Saying About Exxon Mobil</h3>
<p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $130.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Exxon Mobil, maintaining a target price of $134.<br />
&#x2A; An analyst from Scotiabank has decided to maintain their Sector Outperform rating on Exxon Mobil, which currently sits at a price target of $125.<br />
&#x2A; An analyst from Piper Sandler has decided to maintain their Overweight rating on Exxon Mobil, which currently sits at a price target of $131. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Exxon Mobil options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Markets

A Closer Look at Exxon Mobil's Options Market Dynamics

<p>Deep-pocketed investors have adopted a bullish approach towards Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DDOG usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 20 extraordinary options activities for Datadog. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 55% leaning bullish and 35% bearish. Among these notable options, 8 are puts, totaling $284,309, and 12 are calls, amounting to $545,499.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $100.0 to $195.0 for Datadog over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Datadog stands at 1418.17, with a total volume reaching 2,719.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Datadog, situated within the strike price corridor from $100.0 to $195.0, throughout the last 30 days.</p>
<h3>Datadog 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753815783_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$14.85</td>
<td>$13.75</td>
<td>$14.85</td>
<td>$175.00</td>
<td>$81.6K</td>
<td>1.0K</td>
<td align="right">55</td>
</tr>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/29/25</td>
<td>$7.55</td>
<td>$7.3</td>
<td>$7.55</td>
<td>$150.00</td>
<td>$74.7K</td>
<td>193</td>
<td align="right">130</td>
</tr>
<tr>
<td>DDOG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$6.75</td>
<td>$6.65</td>
<td>$6.7</td>
<td>$135.00</td>
<td>$67.0K</td>
<td>1.1K</td>
<td align="right">100</td>
</tr>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$6.2</td>
<td>$5.9</td>
<td>$6.2</td>
<td>$150.00</td>
<td>$66.3K</td>
<td>7.1K</td>
<td align="right">431</td>
</tr>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$17.95</td>
<td>$17.65</td>
<td>$17.7</td>
<td>$150.00</td>
<td>$53.1K</td>
<td>3.3K</td>
<td align="right">45</td>
</tr>
</tbody>
</table>
</p>
<h3>About Datadog</h3>
<p>Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered via software as a service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of applications throughout their businesses.</p>
<p>Having examined the options trading patterns of Datadog, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Datadog</h3>
<ul>
<li>Trading volume stands at 1,468,304, with DDOG's price up by 0.07%, positioned at $150.87.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 9 days.</li>
</ul>
<h3>Expert Opinions on Datadog</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $156.2.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from B of A Securities persists with their Buy rating on Datadog, maintaining a target price of $175.<br />
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Datadog, targeting a price of $165.<br />
&#x2A; An analyst from Guggenheim has revised its rating downward to Sell, adjusting the price target to $105.<br />
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on Datadog, maintaining a target price of $165.<br />
&#x2A; Maintaining their stance, an analyst from Cantor Fitzgerald continues to hold a Overweight rating for Datadog, targeting a price of $171. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Datadog options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


DDOG

A Closer Look at Datadog's Options Market Dynamics

<p>In the last three months, 20 analysts have published ratings on Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Exelixis, presenting an average target of $47.75, a high estimate of $60.00, and a low estimate of $38.00. This current average has increased by 10.02% from the previous average price target of $43.40. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753815782_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The perception of Exelixis by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$49.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Sean Laaman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$45.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Michael Schmitz</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$41.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Jefferson Harralson</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$43.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$53.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$50.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jefferson Harralson</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Exelixis. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Exelixis compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Exelixis's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Exelixis's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Exelixis analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Exelixis</h2>
<p>Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.</p>
<h3>Breaking Down Exelixis's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Exelixis displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>30.62%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Exelixis's net margin excels beyond industry benchmarks, reaching <strong>28.74%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Exelixis's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>7.3%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Exelixis's ROA excels beyond industry benchmarks, reaching <strong>5.52%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Exelixis's debt-to-equity ratio is below the industry average at <strong>0.09</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

EXEL

Assessing Exelixis: Insights From 20 Financial Analysts

<p>Hess Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HESM#NYSE">HESM</a>) will release its quarterly earnings report on Wednesday, 2025-07-30. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Hess Midstream to report an <strong>earnings per share</strong> (EPS) of $0.66.</p>
<p>The announcement from Hess Midstream is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS missed by $0.04 in the last quarter, leading to a 1.29% drop in the share price on the following day.</p>
<p>Here's a look at Hess Midstream's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.69</td>
<td>0.68</td>
<td>0.66</td>
<td>0.63</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.65</td>
<td>0.68</td>
<td>0.63</td>
<td>0.59</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>1.0%</td>
<td>-0.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753815778_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Hess Midstream were trading at $40.34 as of July 28. Over the last 52-week period, shares are up 9.69%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/HESM/earnings"><strong>To track all earnings releases for Hess Midstream visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


HESM

Earnings Preview: Hess Midstream

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Tempus AI</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TEM, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 22 uncommon options trades for Tempus AI.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 63% bullish and 27%, bearish.</p>
<p>Out of all of the special options we uncovered, 5 are puts, for a total amount of $210,365, and 17 are calls, for a total amount of $831,833.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $35.0 to $100.0 for Tempus AI over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Tempus AI stands at 2041.93, with a total volume reaching 2,966.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Tempus AI, situated within the strike price corridor from $35.0 to $100.0, throughout the last 30 days.</p>
<h3>Tempus AI Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753815777_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$16.7</td>
<td>$16.4</td>
<td>$16.7</td>
<td>$60.00</td>
<td>$167.0K</td>
<td>78</td>
<td align="right">129</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$19.5</td>
<td>$19.3</td>
<td>$19.3</td>
<td>$45.00</td>
<td>$90.7K</td>
<td>3.7K</td>
<td align="right">50</td>
</tr>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$7.1</td>
<td>$7.0</td>
<td>$7.06</td>
<td>$50.00</td>
<td>$70.1K</td>
<td>2.8K</td>
<td align="right">135</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$12.2</td>
<td>$12.0</td>
<td>$12.13</td>
<td>$60.00</td>
<td>$60.6K</td>
<td>5.7K</td>
<td align="right">195</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$1.8</td>
<td>$1.7</td>
<td>$1.7</td>
<td>$68.00</td>
<td>$59.5K</td>
<td>90</td>
<td align="right">367</td>
</tr>
</tbody>
</table>
</p>
<h3>About Tempus AI</h3>
<p>Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.</p>
<p>Following our analysis of the options activities associated with Tempus AI, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Tempus AI</h3>
<ul>
<li>With a trading volume of 7,459,075, the price of TEM is down by -4.37%, reaching $59.29.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 10 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Tempus AI</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $75.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Guggenheim continues to hold a Buy rating for Tempus AI, targeting a price of $75. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Tempus AI with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Smart Money Is Betting Big In TEM Options

<p><strong>Compass</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-07-30. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Compass will report an <strong>earnings per share</strong> (EPS) of $0.13. </p>
<p>Compass bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS missed by $0.09, leading to a 19.15% drop in the share price on the subsequent day.</p>
<p>Here's a look at Compass's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0</td>
<td>-0.03</td>
<td>-0.03</td>
<td>0.03</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.09</td>
<td>-0.08</td>
<td>0</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-19.0%</td>
<td>28.000000000000004%</td>
<td>14.000000000000002%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753815769_0.png" alt="eps graph" /></p>
<h3>Compass Share Price Analysis</h3>
<p>Shares of Compass were trading at $7.35 as of July 28. Over the last 52-week period, shares are up 68.45%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/COMP/earnings"><strong>To track all earnings releases for Compass visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


COMP

What's Next: Compass's Earnings Preview

<p>The Chefs' Warehouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>) is preparing to release its quarterly earnings on Wednesday, 2025-07-30. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect The Chefs' Warehouse to report an <strong>earnings per share</strong> (EPS) of $0.46.</p>
<p>The announcement from The Chefs' Warehouse is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.06, leading to a 1.15% increase in the share price on the subsequent day.</p>
<p>Here's a look at The Chefs' Warehouse's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.19</td>
<td>0.51</td>
<td>0.34</td>
<td>0.36</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.25</td>
<td>0.55</td>
<td>0.36</td>
<td>0.40</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>6.0%</td>
<td>2.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753815760_0.png" alt="eps graph" /></p>
<h3>Performance of The Chefs' Warehouse Shares</h3>
<p>Shares of The Chefs' Warehouse were trading at $62.68 as of July 28. Over the last 52-week period, shares are up 48.47%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Insights on The Chefs' Warehouse</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on The Chefs' Warehouse.</p>
<p>Analysts have provided The Chefs' Warehouse with 2 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $70.0, suggesting a potential 11.68% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of United Natural Foods, Andersons and Performance Food Gr, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for United Natural Foods, with an average 1-year price target of $26.0, suggesting a potential 58.52% downside.</li>
<li>Analysts currently favor an Buy trajectory for Andersons, with an average 1-year price target of $50.0, suggesting a potential 20.23% downside.</li>
<li>Analysts currently favor an Buy trajectory for Performance Food Gr, with an average 1-year price target of $104.71, suggesting a potential 67.05% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>In the peer analysis summary, key metrics for United Natural Foods, Andersons and Performance Food Gr are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Chefs' Warehouse</td>
<td>Buy</td>
<td>8.72%</td>
<td>$226.00M</td>
<td>1.91%</td>
</tr>
<tr>
<td>United Natural Foods</td>
<td>Neutral</td>
<td>7.48%</td>
<td>$1.08B</td>
<td>-0.43%</td>
</tr>
<tr>
<td>Andersons</td>
<td>Buy</td>
<td>-2.17%</td>
<td>$152.87M</td>
<td>0.02%</td>
</tr>
<tr>
<td>Performance Food Gr</td>
<td>Buy</td>
<td>10.45%</td>
<td>$1.82B</td>
<td>1.36%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>The Chefs' Warehouse ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the lowest Return on Equity.</p>
<h3>Unveiling the Story Behind The Chefs' Warehouse</h3>
<p>The Chefs' Warehouse Inc is a specialty food distributor in metropolitan areas across the United States and Canada. The company's product portfolio is comprised of imported and local specialty food products such as cheese, cooking oils, chocolates, dried food, baking products, meats, and other food products. It operates via one reporting segment called Food Product Distribution. Operations are concentrated on the east, midwest, and west coasts of the U.S. The company provides service to restaurants, clubs, hotels, caterers, schools, bakeries, casinos, and specialty food stores.</p>
<h3>Breaking Down The Chefs' Warehouse's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> The Chefs' Warehouse's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately <strong>8.72%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> The Chefs' Warehouse's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>1.08%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The Chefs' Warehouse's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>1.91%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The Chefs' Warehouse's ROA excels beyond industry benchmarks, reaching <strong>0.56%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.68</strong>.</p>
<p><a href="https://www.benzinga.com/quote/CHEF/earnings"><strong>To track all earnings releases for The Chefs' Warehouse visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CHEF

Insights into The Chefs' Warehouse's Upcoming Earnings

<p>Bausch &amp; Lomb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) will release its quarterly earnings report on Wednesday, 2025-07-30. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Bausch &amp; Lomb to report an <strong>earnings per share</strong> (EPS) of $0.07.</p>
<p>The market awaits Bausch &amp; Lomb's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS missed by $0.09 in the last quarter, leading to a 0.26% increase in the share price on the following day.</p>
<p>Here's a look at Bausch &amp; Lomb's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.02</td>
<td>0.24</td>
<td>0.22</td>
<td>0.17</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.07</td>
<td>0.25</td>
<td>0.17</td>
<td>0.13</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>-3.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753815746_0.png" alt="eps graph" /></p>
<h3>Tracking Bausch &amp; Lomb's Stock Performance</h3>
<p>Shares of Bausch &amp; Lomb were trading at $14.44 as of July 28. Over the last 52-week period, shares are down 14.11%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BLCO/earnings"><strong>To track all earnings releases for Bausch &amp; Lomb visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BLCO

Examining the Future: Bausch & Lomb's Earnings Outlook

<p>Alignment Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) will release its quarterly earnings report on Wednesday, 2025-07-30. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Alignment Healthcare to report an <strong>earnings per share</strong> (EPS) of $-0.04.</p>
<p>The market awaits Alignment Healthcare's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.02, leading to a 7.39% drop in the share price the following trading session.</p>
<p>Here's a look at Alignment Healthcare's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.07</td>
<td>-0.08</td>
<td>-0.14</td>
<td>-0.14</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.05</td>
<td>-0.16</td>
<td>-0.14</td>
<td>-0.13</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>16.0%</td>
<td>0.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753815737_0.png" alt="eps graph" /></p>
<h3>Tracking Alignment Healthcare's Stock Performance</h3>
<p>Shares of Alignment Healthcare were trading at $11.86 as of July 28. Over the last 52-week period, shares are up 35.47%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Take on Alignment Healthcare</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Alignment Healthcare.</p>
<p>The consensus rating for Alignment Healthcare is Neutral, derived from 1 analyst ratings. An average one-year price target of $17.0 implies a potential 43.34% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Progyny, HealthEquity and Molina Healthcare, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Progyny, with an average 1-year price target of $25.33, suggesting a potential 113.58% upside.</li>
<li>Analysts currently favor an Outperform trajectory for HealthEquity, with an average 1-year price target of $116.88, suggesting a potential 885.5% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Molina Healthcare, with an average 1-year price target of $256.0, suggesting a potential 2058.52% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
<p>The peer analysis summary presents essential metrics for Progyny, HealthEquity and Molina Healthcare, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alignment Healthcare</td>
<td>Neutral</td>
<td>47.46%</td>
<td>$106.03M</td>
<td>-8.76%</td>
</tr>
<tr>
<td>Progyny</td>
<td>Neutral</td>
<td>16.53%</td>
<td>$75.80M</td>
<td>3.39%</td>
</tr>
<tr>
<td>HealthEquity</td>
<td>Outperform</td>
<td>15.04%</td>
<td>$224.31M</td>
<td>2.54%</td>
</tr>
<tr>
<td>Molina Healthcare</td>
<td>Neutral</td>
<td>15.66%</td>
<td>$1.17B</td>
<td>5.72%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Alignment Healthcare is positioned in the middle among its peers for consensus rating. It ranks at the bottom for revenue growth. In terms of gross profit, it is at the bottom compared to its peers. However, Alignment Healthcare is at the top for return on equity.</p>
<h3>Discovering Alignment Healthcare: A Closer Look</h3>
<p>Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.</p>
<h3>Breaking Down Alignment Healthcare's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Alignment Healthcare displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>47.46%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Alignment Healthcare's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-0.98%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Alignment Healthcare's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-8.76%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Alignment Healthcare's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-1.09%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Alignment Healthcare's debt-to-equity ratio surpasses industry norms, standing at <strong>3.05</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<p><a href="https://www.benzinga.com/quote/ALHC/earnings"><strong>To track all earnings releases for Alignment Healthcare visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ALHC

Insights into Alignment Healthcare's Upcoming Earnings

<p>13 analysts have expressed a variety of opinions on Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $256.0, along with a high estimate of $364.00 and a low estimate of $179.00. A decline of 24.54% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753815726_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Molina Healthcare among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Stansel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$184.00</td>
<td>$272.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$180.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$180.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$186.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$312.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$179.00</td>
<td>$373.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$216.00</td>
<td>$372.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$335.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$330.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$266.00</td>
<td>$364.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$347.00</td>
<td>$351.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$364.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$351.00</td>
<td>$362.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Molina Healthcare. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Molina Healthcare compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Molina Healthcare's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Capture valuable insights into Molina Healthcare's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MOH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Molina Healthcare analyst ratings.</strong></a></p>
<h2>Get to Know Molina Healthcare Better</h2>
<p>Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.</p>
<h3>Understanding the Numbers: Molina Healthcare's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, Molina Healthcare showcased positive performance, achieving a revenue growth rate of <strong>15.66%</strong> as of 30 June, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Molina Healthcare's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>2.23%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Molina Healthcare's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>5.72%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Molina Healthcare's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.56%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Molina Healthcare's debt-to-equity ratio is below the industry average at <strong>0.77</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Deep Dive Into Molina Healthcare Stock: Analyst Perspectives (13 Ratings)

<p>Albany Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIN#NYSE">AIN</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-07-30. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Albany Intl will report an <strong>earnings per share</strong> (EPS) of $0.73.</p>
<p>Albany Intl bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>Last quarter the company beat EPS by $0.11, which was followed by a 5.4% drop in the share price the next day.</p>
<p>Here's a look at Albany Intl's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.62</td>
<td>0.66</td>
<td>0.57</td>
<td>0.91</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.73</td>
<td>0.58</td>
<td>0.80</td>
<td>0.89</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>-6.0%</td>
<td>-4.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753815723_0.png" alt="eps graph" /></p>
<h3>Albany Intl Share Price Analysis</h3>
<p>Shares of Albany Intl were trading at $72.33 as of July 28. Over the last 52-week period, shares are down 23.71%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analysts' Perspectives on Albany Intl</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Albany Intl.</p>
<p>Analysts have provided Albany Intl with 2 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $71.0, suggesting a potential 1.84% downside.</p>
<h3>Peer Ratings Comparison</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Standex International, Kennametal and Hillman Solns, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Standex International, with an average 1-year price target of $213.33, suggesting a potential 194.94% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Kennametal, with an average 1-year price target of $23.0, suggesting a potential 68.2% downside.</li>
<li>Analysts currently favor an Buy trajectory for Hillman Solns, with an average 1-year price target of $8.75, suggesting a potential 87.9% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for Standex International, Kennametal and Hillman Solns, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albany International</td>
<td>Neutral</td>
<td>-7.84%</td>
<td>$96.49M</td>
<td>1.88%</td>
</tr>
<tr>
<td>Standex International</td>
<td>Outperform</td>
<td>17.21%</td>
<td>$82.43M</td>
<td>3.26%</td>
</tr>
<tr>
<td>Kennametal</td>
<td>Neutral</td>
<td>-5.70%</td>
<td>$156.37M</td>
<td>2.56%</td>
</tr>
<tr>
<td>Hillman Solns</td>
<td>Buy</td>
<td>2.58%</td>
<td>$168.60M</td>
<td>-0.03%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Albany Intl ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, Albany Intl is at the bottom.</p>
<h3>All You Need to Know About Albany Intl</h3>
<p>Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.</p>
<h3>Breaking Down Albany Intl's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Albany Intl's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately <strong>-7.84%</strong>. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> Albany Intl's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>6.01%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Albany Intl's ROE excels beyond industry benchmarks, reaching <strong>1.88%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Albany Intl's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.04%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Albany Intl's debt-to-equity ratio is below the industry average. With a ratio of <b>0.46</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/AIN/earnings"><strong>To track all earnings releases for Albany Intl visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look Ahead: Albany Intl's Earnings Forecast

<p>In the latest quarter, 10 analysts provided ratings for Principal Financial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $82.0, with a high estimate of $101.00 and a low estimate of $67.00. Marking an increase of 4.33%, the current average surpasses the previous average price target of $78.60. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753815714_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A clear picture of Principal Financial Group's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Nadel</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$87.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$75.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$73.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$90.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$101.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$80.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$89.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$71.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$87.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$67.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Principal Financial Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Principal Financial Group compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Principal Financial Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Principal Financial Group's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PFG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Principal Financial Group analyst ratings.</strong></a></p>
<h2>About Principal Financial Group</h2>
<p>Principal Financial Group Inc is a financial services provider. It offers various financial products and services including retirement, asset management, and workplace benefits and protection solutions to individuals and institutional clients. The company, along with its subsidiaries, operates in the following reportable segments; Retirement and Income Solutions, Principal Asset Management, and Benefits and Protection. Maximum revenue is generated from the Retirement and Income Solutions segment which provides workplace savings and retirement solutions, banking, trust and custodial services, individual variable annuities (including RILAs), pension risk transfer, and investment services to businesses, their employees, and other individuals.</p>
<h3>Principal Financial Group: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Challenges:</strong> Principal Financial Group's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately <strong>-8.82%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Principal Financial Group's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>1.3%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Principal Financial Group's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>0.43%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Principal Financial Group's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.02%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.39</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Principal Financial Group Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)

<p>Enact Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-07-30. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Enact Holdings will report an <strong>earnings per share</strong> (EPS) of $1.11.</p>
<p>Enact Holdings bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.01, leading to a 2.18% increase in the share price the following trading session.</p>
<p>Here's a look at Enact Holdings's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.09</td>
<td>1.03</td>
<td>1.01</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.10</td>
<td>1.09</td>
<td>1.16</td>
<td>1.27</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>1.0%</td>
<td>-2.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753815707_0.png" alt="eps graph" /></p>
<h3>Enact Holdings Share Price Analysis</h3>
<p>Shares of Enact Holdings were trading at $35.11 as of July 28. Over the last 52-week period, shares are up 3.69%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Observations about Enact Holdings</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Enact Holdings.</p>
<p>Analysts have provided Enact Holdings with 4 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $39.5, suggesting a potential 12.5% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of  and PennyMac Financial Servs, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<h3>Peers Comparative Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for  and PennyMac Financial Servs are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>PennyMac Financial Servs</td>
<td>Outperform</td>
<td>-12.93%</td>
<td>$687.05M</td>
<td>3.44%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Enact Holdings ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. However, it is in the middle for Return on Equity.</p>
<h3>Get to Know Enact Holdings Better</h3>
<p>Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The principal mortgage insurance customers are originators of residential mortgage loans who determine which mortgage insurer or insurers will be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.</p>
<h3>Enact Holdings: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Enact Holdings displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>5.25%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Enact Holdings's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>54.02%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Enact Holdings's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>3.28%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Enact Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.5%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Enact Holdings's debt-to-equity ratio is below the industry average at <strong>0.15</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/ACT/earnings"><strong>To track all earnings releases for Enact Holdings visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Preview: Enact Holdings's Earnings

<p><a href="https://www.llnl.gov/article/53006/el-capitan-reigns-supreme-across-three-major-supercomputing-benchmarks">https://www.llnl.gov/article/53006/el-capitan-reigns-supreme-across-three-major-supercomputing-benchmarks</a></p>


General

'El Capitan Reigns Supreme Across Three Major Supercomputing Benchmarks'

Press Releases

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

Health Care

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Comments

Pyxis Oncology

Pyxis Oncology (PYXS) Opciones

Pyxis Oncology (NASDAQ:PYXS) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL